—
C+
C+ The full Closelook — membership. Open the C+ overview

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Amneal Pharmaceuticals, Inc. Class A Common Stock

AMRX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Amneal Pharmaceuticals develops, makes and distributes generic and specialty drugs, including injectables and biosimilars, from sites in the United States, India and Ireland. It groups its business into affordable generics, a specialty unit built around central nervous system and thyroid treatments such as Rytary and Unithroid, and a government-supply arm, AvKARE, that serves defence and veterans' health agencies. It sells through wholesalers, distributors, retail pharmacies and hospitals rather than direct to patients.
Where it sits in the stack
Amneal sits outside our AI build-out indices; it belongs to the healthcare sleeve of our universe, under specialty and generic drug manufacturing, with no seat in Rubin or Halo.
Who it is priced against
The diary has no peer group listed for Amneal in our data; the comparison the market draws is with other generic-drug makers such as Viatris.
Why Closelook tracks it
Amneal carries no index seat, no Closelook score and no quotes in our editions; coverage here rests only on its chart structure, not on any scored module.
What the diary watches
Whether the specialty segment's newer treatments, such as CREXONT, start to shift revenue away from the lower-margin generics business.

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 53/100 composite (momentum 85, quality 56, valuation 43) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for AMRX, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Barclays, 2026-09-17

The Street on this name

Analyst actions and the latest print for AMRX from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Barclays — target 20 from 16 Target raised to $20 from $16 (+10.6% to spot) 2026-09-17

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against AMRX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What AMRX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +5.1% in FY2025 32 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sector × region Health care in US: +0.7% week · +0.4% month · +10.2% quarter · +6.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-16
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)?

Amneal Pharmaceuticals, Inc. Class A Common Stock trades as AMRX on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-18.

Is AMRX in a Closelook index?

Not currently — Amneal Pharmaceuticals, Inc. Class A Common Stock is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

What is Amneal Pharmaceuticals, Inc. Class A Common Stock's Closelook composite score?

53 out of 100, with momentum 85, quality 56 and valuation 43 sub-scores, as of 2026-09-18. Scores are Closelook's own research readings, not ratings or investment advice.

Where does AMRX trade against its moving averages?

Uptrend stack intact: Trades +2.7% vs the 50-day and +25.4% vs the 200-day average, 5.1% below the 52-week high and +92.6% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Amneal Pharmaceuticals, Inc. Class A Common Stock do?

Amneal Pharmaceuticals develops, makes and distributes generic and specialty drugs, including injectables and biosimilars, from sites in the United States, India and Ireland. It groups its business into affordable generics, a specialty unit built around central nervous system and thyroid treatments such as Rytary and Unithroid, and a government-supply arm, AvKARE, that serves defence and veterans' health agencies. It sells through wholesalers, distributors, retail pharmacies and hospitals rather than direct to patients. The diary has no peer group listed for Amneal in our data; the comparison the market draws is with other generic-drug makers such as Viatris.

Where does Amneal Pharmaceuticals, Inc. Class A Common Stock sit in the AI build-out?

Amneal sits outside our AI build-out indices; it belongs to the healthcare sleeve of our universe, under specialty and generic drug manufacturing, with no seat in Rubin or Halo. Amneal carries no index seat, no Closelook score and no quotes in our editions; coverage here rests only on its chart structure, not on any scored module.

Does Amneal Pharmaceuticals, Inc. Class A Common Stock pay a dividend?

No cash distribution shows in Amneal Pharmaceuticals, Inc. Class A Common Stock’s price series over the last three years. The share count rose 5.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Amneal Pharmaceuticals, Inc. Class A Common Stock recently?

The most recent analyst action on Amneal Pharmaceuticals, Inc. Class A Common Stock on the Closelook wire is a price target by Barclays on 2026-09-17 (target 20 from 16). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for AMRX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.